Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Work In Process: 2021-2024

Historic Work In Process for Mirum Pharmaceuticals (MIRM) over the last 4 years, with Dec 2024 value amounting to $16.1 million.

  • Mirum Pharmaceuticals' Work In Process rose 28.38% to $18.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.3 million, marking a year-over-year increase of 28.38%. This contributed to the annual value of $16.1 million for FY2024, which is 62.96% up from last year.
  • As of FY2024, Mirum Pharmaceuticals' Work In Process stood at $16.1 million, which was up 62.96% from $9.9 million recorded in FY2023.
  • Over the past 5 years, Mirum Pharmaceuticals' Work In Process peaked at $16.1 million during FY2024, and registered a low of $570,000 during FY2021.
  • Its 3-year average for Work In Process is $10.4 million, with a median of $9.9 million in 2023.
  • Data for Mirum Pharmaceuticals' Work In Process shows a peak YoY soared of 838.77% (in 2022) over the last 5 years.
  • Over the past 4 years, Mirum Pharmaceuticals' Work In Process (Yearly) stood at $570,000 in 2021, then surged by 838.77% to $5.4 million in 2022, then soared by 84.51% to $9.9 million in 2023, then spiked by 62.96% to $16.1 million in 2024.